

104.201-12 – including *Taq* polymerase

104.201-12u – without *Taq* polymerase

Lot No.: **5S6**

Lot-specific information

Visit www.caredx.com for
“Instructions for Use” (IFU)

Olerup SSP[®] KIR HLA Ligand

Product number:	104.201-12 – including <i>Taq</i> polymerase 104.201-12u – without <i>Taq</i> polymerase
Lot number:	5S6
Expiry date:	2027-10-01
Number of tests:	12
Number of wells per test:	7+1
Storage - pre-aliquoted primers:	dark, between -15°C and -25°C
- PCR Master Mix:	between -15°C and -25°C
- Adhesive PCR seals	RT

This Product Description is only valid for Lot No. 5S6.

Complete product documentation consists of generic Instructions for Use (IFU), lot specific Product Insert, Worksheet and Certificate.

CHANGES COMPARED TO THE PREVIOUS OLERUP SSP[®] KIR HLA LIGAND LOT (8N3)

- The product documentation has been updated for new alleles of IMGT 3.53.0.

The KIR HLA Ligand specificity and interpretation tables have been updated for the HLA-A, HLA-B and HLA-C alleles described since the previous *Olerup SSP[®]* KIR HLA Ligand lot was made (**Lot No. 8N3**).

The KIR HLA Ligand primer set is unchanged compared to the previous *Olerup* KIR HLA Ligand lot (**Lot No. 8N3**).



104.201-12 – including *Taq* polymerase

104.201-12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **5S6**

Lot-specific information

Well **8** contains Negative Control primer pairs, that will amplify the majority of the *Olerup* SSP® HLA Class I, DRB, DQB1, DPB1 and DQA1 amplicons as well as all the amplicons generated by the control primer pairs matching the human growth hormone gene.

HLA-specific PCR product sizes range from 75 to 200 base pairs.

The PCR product generated by the positive control primer pair is 200 base pairs.

Length of PCR product	105	200	105	80	75	80	85
5'-primer¹	164	340	440	45	45	43	36
	5'-CAC ^{3'}	5'-Agg ^{3'}	5'-TTA ^{3'}	5'-Tgg ^{3'}	5'-Tgg ^{3'}	5'-Tgg ^{3'}	5'-TAC ^{3'}
							36
							5'-TAT ^{3'}
3'-primer²	231	2nd I	507	59	58	57	47
	5'-TgC ^{3'}	5'-AAA ^{3'}	5'-TTg ^{3'}	5'-CTC ^{3'}	5'-ggC ^{3'}	5'-CTC ^{3'}	5'-ACA ^{3'}
							48
							5'-gCA ^{3'}
							48
							5'-gCC ^{3'}
							52
							5'-TgT ^{3'}
A*	+	+	+				
B*	+	+	+				
C*	+	+	+				
DRB1				+	+		
DRB3				+	+		
DRB5				+			
DQB1					+		
DPB1						+	
DQA1							+

¹The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

²The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2nd or 3rd exon or the 2nd intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.



104.201-12 – including *Taq* polymerase
104.201-12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **5S6**

Lot-specific information

PRODUCT DESCRIPTION

KIR HLA Ligand SSP typing

CONTENT

The primer set contains 5'- and 3'-primers for determining KIR HLA Ligand nucleotide sequence motifs;

HLA-A^{Bw4+} alleles,

HLA-B^{Bw4+} alleles encoding Isoleucine or Threonine at position 80,

HLA-B^{Bw4+} alleles encoding Aspartic acid at position 77 and Threonine at position 80,

HLA-B^{Bw6+} alleles encoding Asparagine at position 80,

HLA-C alleles encoding Asparagine or Lysine at position 80.

PLATE LAYOUT

Each test consists of 8 PCR reactions in an 8 well cut PCR plate.

1	2	3	4	5	6	7	NC
---	---	---	---	---	---	---	----

The 8 well cut PCR plate is marked with '5S6' in silver/gray ink.

Well No. 1 is marked with the Lot Number '5S6'.

Wells 1 and 2: HLA-C KIR ligand primers.

Wells 3, 4, 6 and 7: HLA-B KIR ligand primers.

Well 5: HLA-A KIR ligand primers.

Well 8 – Negative Control (NC).

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded.

The PCR plates are covered with a PCR-compatible foil.

Please note: When removing each 8 well PCR plate, make sure that the remaining plates stay covered. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

UNIQUELY IDENTIFIED ALLELES

The HLA-A, HLA-B and HLA-C alleles recognized by the HLA Nomenclature Committee in July 2023^{1,2,3} have been considered in the Specificity and Interpretation Tables.

¹A minor subset of rare B and C alleles with the listed target motifs will not be amplified by the kit due to downstream sequence variations.

²HLA-A, HLA-B and HLA-C alleles listed on the IMGT/HLA web page 2023-July-12, release 3.53.0, www.ebi.ac.uk/imgt/hla.

³Alleles that have been deleted from or renamed in the official WHO HLA Nomenclature up to and including the last IMGT/HLA database release can be retrieved from web page <http://hla.alleles.org/alleles/deleted.html>.



104.201-12 – including *Taq* polymerase

104.201-12u – without *Taq* polymerase

Lot No.: **5S6**

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot-specific information

PROTOCOL

DNA EXTRACTION

Extracted, highly pure DNA is needed for SSP typings. DNA samples to be used for PCR-SSP HLA typing should be re-suspended in dH₂O. The A260/A280 ratio should be 1.6 – 2.0 by UV spectrophotometry for optimal band visualization during electrophoresis.

We recommend automated DNA extraction with the QIAGEN EZ1 DSP DNA Blood System. ACD blood should be used as starting material.

Alternatively, the DNA can be extracted by any preferred method yielding pure DNA. When using alternative methods, the DNA concentration should be adjusted to 30 ng/μl. **Do not use heparinised blood with these methods.**

Recommended DNA concentration using:
EZ1-extracted DNA, 15 ng/μl.
DNA extracted by other methods, 30 ng/μl.

Concentrations exceeding 50 ng/μl will increase the risk for nonspecific amplifications and weak extra bands, especially for HLA Class I high resolution SSP typings. If necessary, dilute the extracted DNA in dH₂O.

DNA samples should not be re-suspended in solutions containing chelating agents such as EDTA, above 0.5 mM in concentration.

DNA samples may be used immediately after extraction or stored at +4°C for up to 2 weeks with no adverse effects on results. DNA samples can be stored at -20°C or colder for 9 months. The purity and concentration of extracted DNA samples that have been stored for a prolonged period should be tested for acceptability prior to HLA typing.

DNA samples should be shipped at +4°C or colder to preserve their integrity during transport.

PCR AMPLIFICATION

104.201-12 – including *Taq* polymerase

For one KIR HLA Ligand typing, begin by adding to well 8, i.e. the well with the negative control primer pairs:

7 μl dH₂O

3 μl PCR Master Mix complete with *Taq*,

then add at room temperature in a 0.5 ml tube:

9 x 2 μl = 18 μl DNA (30 ng/μl)

9 x 3 μl = 27 μl PCR Master Mix with *Taq* – mix well before taking your aliquot

9 x 5 μl = 45 μl dH₂O



104.201-12 – including *Taq* polymerase

104.201-12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: 5S6

Lot-specific information

Mix well, dispense 10 µl of the DNA-PCR Master Mix-H₂O mixture into each of the 7 wells of a KIR HLA Ligand typing, i.e. wells 1 to 7. Cover the primer tray(s) with the provided adhesive seals. Check that all reaction wells are completely covered to prevent evaporative loss during PCR amplification.

104.201-12u – without *Taq* polymerase

For one KIR HLA Ligand typing, begin by adding at room temperature in a 0.5 ml tube:

10 x 3 µl = 30 µl PCR Master Mix without *Taq* – mix well before taking your aliquot

0,8 µl *Taq* polymerase (5 units/µl)

Mix well, dispense 3 µl of the PCR Master Mix-*Taq* mixture from the 0.5 ml tube into well No. 8, i.e. the well with the negative control primer pairs. Then add 7 µl dH₂O to well 8.

Then add at room temperature to the 0.5 ml tube containing 30 + 0,8 - 3 = 27,8 µl PCR Master Mix-*Taq* mixture:

9 x 2 µl = 18 µl DNA (30 ng/µl)

9 x 5 µl – 0.8 µl = 44.2 µl dH₂O

Mix well, dispense 10 µl of the DNA-PCR Master Mix-*Taq*-H₂O mixture into each of the 7 wells of a KIR HLA Ligand typing, i.e. wells 1 to 7. Cover the primer tray(s) with the provided adhesive seals. Check that all reaction wells are completely covered to prevent evaporative loss during PCR amplification.

Use a 96 well thermal cycler with a heated lid. The temperature gradient across the heating block should be < 1°C.

PCR cycling parameters:

1. 1 cycle	94°C	2 min	denaturation
2. 10 cycles	94°C	10 sec.	denaturation
	65°C	60 sec.	annealing and extension
3. 20 cycles	94°C	10 sec.	denaturation
	61°C	50 sec.	annealing
	72°C	30 sec.	extension
4. End - hold	RT		if less than 8 hours
	4°C		if longer than 8 hours

Total reaction volume in each well, 10 µl.

The same PCR cycling parameters are used for all the *Olerup SSP*[®] kits.

AGAROSE GEL ELECTROPHORESIS

Prepare a 2% (w/v) agarose gel in 0.5 x TBE buffer. Dissolve the agarose by boiling in a microwave oven. Let the gel solution cool to 60°C. Stain the gel prior



104.201-12 – including *Taq* polymerase

104.201-12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **5S6**

Lot-specific information

to casting with ethidium bromide (10 mg/ml), 5 µl per 100 ml gel solution. For maximal ease of handling use our ethidium bromide dropper bottle (Product No. 103.301-10), 1 drop of ethidium bromide solution per 50-75 ml of gel, or our GelRed™ dropper bottle (Product No. 103.302-05) 4 drops per 100-120 ml of gel solution. **Note: Ethidium bromide is a powerful carcinogen. Handle with appropriate personal protective equipment.**

Load the PCR products, preferably using an 8-channel pipette. Load a DNA size marker (100 base pair ladder, Product No. 103.202-100 or DNA Size Marker for short gel runs 103.203-100) in one well per row.

Run the gel in 0.5 x TBE buffer, without re-circulation of the buffer, for 15-20 minutes at 8-10 V/cm.

DOCUMENTATION AND INTERPRETATION

Put the gel on a UV transilluminator and document by photography.

Record the presence and absence of specific PCR products. The relative lengths of the specific PCR products are helpful in the interpretation of the results.

Record the presence and relative lengths of the internal positive control bands. The differently sized control bands will help in the correct orientation of the typing as well as in kit identification.

Lanes without either control band or specific PCR products should be repeated.

Interpret the typings with the ***lot-specific Interpretation and Specificity Tables***.

PCR MASTER MIXES

The PCR Master Mix complete with *Taq* polymerase contains:

<i>Taq</i> polymerase	0.4 unit per 10 µl SSP reaction
nucleotides	final concentration of each dNTP is 200 µM
PCR buffer	final concentrations: 50 mM KCl, 1.5 mM MgCl ₂ , 10 mM Tris-HCl pH 8.3, 0.001% w/v gelatin
glycerol	final concentration of glycerol is 5%
cresol red	final concentration of cresol red is 100 µg/ml

The same PCR Master Mix complete with *Taq* is used for all Olerup SSP® kits.

The PCR Master Mix without *Taq* polymerase contains:

nucleotides	final concentration of each dNTP is 200 µM
PCR buffer	final concentrations: 50 mM KCl, 1.5 mM MgCl ₂ , 10 mM Tris-HCl pH 8.3, 0.001% w/v gelatin
glycerol	final concentration of glycerol is 5%
cresol red	final concentration of cresol red is 100 µg/ml

The same PCR Master Mix without *Taq* is used for all Olerup SSP® kits.



104.201-12 – including *Taq* polymerase

104.201-12u – without *Taq* polymerase

Lot No.: **5S6**

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot-specific information
SPECIFICITY TABLE

KIR HLA Ligand SSP typing

Specificities and sizes of the PCR products of the 7+1 primer mixes used for KIR HLA Ligand SSP.

Primer Mix	Size of spec. PCR product ¹	Size of control band ²	KIR HLA Ligand nucleotide sequence motif	Amplified HLA alleles ^{3,4}
1 ⁷	345 bp	800 bp	HLA-C ^{Asn80}	C*01:02:01:01-01:02:50, 01:02:52-01:02:88, 01:02:90-01:13, 01:15:01-01:45, 01:47-01:153, 01:155-01:170, 01:172-01:253, 02:27:01-02:27:02, 02:65, 02:87, 02:115, 02:131, 03:02:01-03:04:94, 03:04:96-03:06:02, 03:08-03:09, 03:11:01-03:11:02, 03:13:01:01-03:14, 03:16-03:28, 03:30-03:44, 03:46-03:98, 03:100-03:162, 03:164-03:267, 03:269-03:296:02, 03:298-03:394, 03:396:01N, 03:397-03:398, 03:400-03:414, 03:416-03:437, 03:439-03:449N, 03:451-03:460, 03:462N-03:500, 03:502Q-03:626, 03:628N-03:640, 04:11, 04:29, 04:36, 04:55, 04:114, 04:172, 04:346, 04:383, 04:473, 05:20, 06:11, 06:82, 06:147, 06:210, 06:217, 06:248, 06:252, 07:01:01:01-07:01:02:15, 07:01:04-07:06:06, 07:08, 07:10-07:33N, 07:35-07:75, 07:77-07:78:01, 07:79-07:114, 07:116-07:294, 07:296-07:314:03, 07:316-07:327, 07:329N-07:360, 07:362-07:405:02, 07:407-07:425, 07:427-07:458, 07:460-07:477, 07:479-07:558:01:02, 07:560-07:575:02, 07:577-07:597, 07:599-07:655, 07:657-07:672N, 07:674-07:715:02, 07:717-07:913, 07:915-07:950, 07:952-07:1052, 07:1054N-07:1082, 08:01:01:01-08:01:07, 08:01:09-08:09, 08:11-08:63, 08:65-08:145, 08:147-08:270, 12:02:01-12:02:22, 12:02:24-12:03:69, 12:03:71-12:03:83, 12:06-12:08, 12:10:01-12:20, 12:22-12:32, 12:34, 12:36-12:40, 12:42Q-12:59, 12:61-12:71, 12:73-12:134, 12:136-12:145, 12:147-12:153, 12:155Q-12:229, 12:231-12:298, 12:300-12:352, 12:354-12:389, 14:02:01:01-14:11, 14:13-14:48, 14:50-14:107, 14:109-14:154, 15:07:01:01-15:07:01:02, 15:25, 15:43, 15:85, 15:144, 15:181, 16:01:01:01-16:01:43, 16:04:01:01-16:04:01:03, 16:04:03-16:04:05, 16:06-16:08, 16:10-16:11, 16:13-16:18, 16:20-16:24, 16:26-16:36, 16:38-16:45, 16:49:01-16:59, 16:61-16:62, 16:64-16:68, 16:71-16:73, 16:75-16:76, 16:78-16:83, 16:86-16:87, 16:92-16:93, 16:95-16:98, 16:100,



104.201-12 – including *Taq* polymerase

104.201-12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: 5S6

Lot-specific information

				16:105-16:106, 16:109-16:114, 16:116-16:119, 16:122, 16:124-16:128, 16:130-16:131, 16:134-16:135, 16:137-16:139, 16:141-16:142, 16:146-16:152, 16:154, 16:157-16:162, 16:164-16:165, 16:168-16:175, 16:177-16:178, 16:180, 16:182-16:183, 16:185-16:193, 16:196-16:198, 16:200-16:201, 16:203-16:211, 17:22
2⁸	350 bp	800 bp	HLA-C^{Lys80}	C*01:14, 01:154, 02:02:01-02:02:03, 02:02:06-02:26:03, 02:28-02:40:02, 02:42-02:64, 02:66-02:86, 02:88-02:114, 02:116-02:130, 02:132-02:186, 02:188-02:223N, 03:07:01:01-03:07:02, 03:10, 03:15, 03:29, 03:45, 03:163, 03:268, 03:297, 03:450, 03:461, 04:01:01:01-04:01:01:29, 04:01:01:31-04:01:131, 04:01:133-04:01:153, 04:03:01:01-04:10, 04:12-04:20, 04:23-04:28, 04:30-04:35:02, 04:37-04:54:02, 04:56-04:113, 04:115N-04:171, 04:173N-04:249, 04:251-04:345, 04:347-04:382Q, 04:384-04:472, 04:474-04:507, 05:01:01:01-05:01:75, 05:03-05:19, 05:21-05:244N, 05:246-05:285, 06:02:01:01-06:02:01:94, 06:02:03-06:02:86, 06:02:88-06:02:90, 06:02:92-06:10, 06:12-06:81, 06:83-06:146, 06:148-06:209:02, 06:211:01:01N-06:216, 06:218-06:247, 06:249-06:251, 06:253-06:364, 07:07, 07:09, 07:76:01-07:76:02, 07:315, 07:328, 07:406, 07:559, 07:598, 07:656, 07:914, 08:10, 12:04:01-12:05:02, 12:09, 12:21, 12:33, 12:41, 12:60, 12:72, 12:135, 12:146, 12:154, 12:353, 14:12, 14:49, 14:108, 15:02:01:01-15:05:07, 15:05:09-15:06:03, 15:08:01-15:13:02, 15:15-15:19, 15:21-15:24, 15:26-15:42, 15:44:01-15:84Q, 15:86-15:143, 15:145N-15:180, 15:182-15:260, 16:02:01:01-16:02:20, 16:09, 16:12, 16:19, 16:25, 16:37, 16:46-16:48, 16:60, 16:63, 16:69-16:70, 16:74, 16:77N, 16:84, 16:88-16:91, 16:99, 16:101-16:104, 16:107-16:108, 16:115, 16:120-16:121, 16:123N, 16:132N-16:133, 16:136, 16:140, 16:143-16:145, 16:153, 16:155-16:156, 16:163, 16:166-16:167, 16:176, 16:179, 16:181, 16:184, 16:194-16:195N, 16:202, 17:01:01:02-17:21, 17:23-17:71, 18:01:01:01-18:19
3⁵	350 bp	800 bp	HLA-B^{Bw4+Thr80}	B*07:149, 07:453, 08:02, 08:117, 08:255, 08:271, 13:01:01:01-13:04, 13:06-13:08, 13:10-13:23, 13:25-13:38, 13:40-13:66, 13:68-13:180, 14:118, 15:36, 15:89:01-15:89:02, 15:115, 15:256, 15:339, 15:505, 18:09, 27:01, 27:142, 37:01:02, 37:10, 38:02:01:01-38:04, 38:08, 38:15, 38:18, 38:23, 38:29, 38:35, 38:43-38:50, 38:62, 38:64, 38:72, 38:74-38:76, 38:79, 38:82,



104.201-12 – including *Taq* polymerase

104.201-12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: 5S6

Lot-specific information

				38:84-38:85, 38:89, 38:92, 38:97-38:98, 38:103N-38:105, 38:160, 38:162-38:165N, 38:167, 38:172-38:173Q, 40:47, 40:96, 40:110, 40:157, 40:201, 44:02:01:01-44:02:44, 44:02:46-44:05:02, 44:05:04-44:05:06, 44:07-44:08, 44:10-44:17, 44:19N-44:24, 44:26-44:45, 44:47-44:49, 44:51-44:74, 44:76-44:89, 44:91-44:94, 44:96-44:128:02, 44:130, 44:132-44:151, 44:153-44:169, 44:171N-44:195N, 44:197-44:245:02, 44:247-44:253, 44:255-44:256, 44:258-44:276, 44:278-44:344, 44:346-44:354N, 44:357-44:359, 44:361-44:374, 44:437, 44:439-44:453, 44:456-44:524, 44:526-44:544N, 44:546, 47:04, 47:11, 48:56, 49:02, 49:70, 51:54, 51:78:01-51:78:02, 51:341, 51:371, 52:20, 53:09, 53:11-53:13, 53:31, 53:36, 53:38, 53:67, 56:07, 58:137, 59:08
4 ⁵	350 bp	1070 bp	HLA-B ^{Bw4+Ile80}	B*07:36, 07:38, 07:81, 07:180, 07:219, 08:03, 08:52, 08:78, 14:93, 15:13:01-15:13:03, 15:16:01:01-15:17:07, 15:23-15:24:02, 15:67, 15:87, 15:95, 15:157, 15:162, 15:168, 15:177, 15:196, 15:208, 15:216, 15:222, 15:230, 15:254, 15:268, 15:273, 15:356, 15:361-15:362, 15:396, 15:403, 15:408, 15:411, 15:418, 15:423-15:424, 15:442, 15:446, 15:462, 15:500, 15:516, 15:523, 15:532, 15:546Q, 15:550, 15:555, 15:575N, 15:586, 15:602-15:603, 15:613, 15:619, 15:642, 15:644, 15:655, 18:67, 18:136, 18:194:01:01-18:194:01:02, 27:02:01:01-27:02:06, 27:30, 27:53, 27:57, 27:62, 27:65N, 27:75, 27:77, 27:83, 27:95, 27:102, 27:119, 27:126, 27:134, 27:157, 27:163, 27:171-27:172, 27:176N, 27:181, 27:188, 27:197, 27:203, 27:213, 27:232, 27:236, 27:245-27:246N, 27:251, 35:471, 37:34, 38:01:01:01-38:01:22, 38:05-38:07, 38:09-38:14, 38:16, 38:19-38:22, 38:24-38:28, 38:30-38:34N, 38:36-38:42, 38:51-38:61, 38:63, 38:65-38:71, 38:73, 38:77-38:78, 38:80N-38:81, 38:83N, 38:86-38:88, 38:90-38:91, 38:93-38:96, 38:99-38:102, 38:106-38:111, 38:161, 38:166, 38:168-38:171, 40:13, 40:19, 40:109, 40:117, 40:292, 40:340, 40:394, 41:46, 41:60, 44:06, 44:18:01:01-44:18:01:02, 44:25, 44:50:01, 44:50:03, 44:95, 44:355, 48:18, 49:01:01:01-49:01:24, 49:03-49:14, 49:16-49:69, 49:71-49:81, 51:01:01:01-51:24:05, 51:26-51:46, 51:48-51:53, 51:55-51:77, 51:79-51:340, 51:342-51:370, 51:372-51:386, 52:01:01:01-52:01:28, 52:01:30-52:19, 52:21:01-52:115N, 53:01:01:01-53:02, 53:04-53:08:02, 53:10, 53:14-53:30, 53:32-53:35, 53:37, 53:39-53:54,



104.201-12 – including Taq polymerase

104.201-12u – without Taq polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: 5S6

Lot-specific information

				53:56-53:66, 53:68-53:73, 54:12, 55:103, 56:21, 56:65, 57:01:01:01-57:11, 57:13-57:167, 58:01:01:01-58:02:02, 58:04-58:16:02, 58:18-58:29, 58:31N-58:63, 58:65-58:136, 58:138-58:143, 59:01:01:01-59:07, 59:09-59:12
5	370 bp	1070 bp	HLA-A ^{Bw4+}	A*01:95, 01:289, 01:298, 02:81, 02:87, 02:112, 02:124, 02:129, 02:136, 02:571, 02:829, 03:152, 03:219, 11:178, 11:190, 23:01:01:01-23:68, 23:70-23:89, 23:91N-23:111, 23:114-23:121, 23:123-23:131, 24:02:01:01-24:02:163, 24:02:165-24:03:04, 24:05:01-24:11N, 24:13:01-24:15, 24:17:01:01-24:18, 24:20:01:01-24:27, 24:29-24:43, 24:45N-24:64, 24:66-24:88, 24:90:01N-24:99, 24:101-24:108, 24:110-24:128, 24:130-24:210, 24:212-24:240N, 24:242-24:289, 24:291-24:372, 24:374-24:405, 24:407-24:423, 24:425N-24:470, 24:472-24:608N, 25:01:01:01-25:58, 25:60-25:86, 29:13, 31:07-31:08, 31:10, 31:222, 32:01:01:01-32:175, 68:36, 68:249
6	350 bp	1070 bp	HLA-B ^{Bw4+, Thr80}	B*07:27, 07:236, 07:273, 08:126, 15:43, 15:594, 18:54, 18:195, 27:03-27:05:36, 27:05:38-27:05:58, 27:06:01:01-27:07:06, 27:09-27:11, 27:13:01-27:17, 27:19:01:01-27:21:02, 27:23-27:25, 27:27-27:29, 27:31-27:32, 27:34-27:39, 27:41, 27:43, 27:45-27:48, 27:50:01-27:52, 27:54-27:56, 27:58-27:61, 27:63-27:64N, 27:66N-27:74, 27:76, 27:78-27:82, 27:84-27:88, 27:90:01-27:94N, 27:96:01-27:101, 27:103-27:118, 27:120-27:125, 27:127-27:133, 27:135-27:141, 27:143-27:152, 27:154-27:155, 27:158-27:162, 27:164, 27:166-27:170, 27:173-27:175, 27:177-27:180, 27:182-27:187, 27:189-27:196, 27:198-27:202, 27:205-27:212N, 27:214, 27:216-27:231, 27:233-27:235, 27:237-27:241, 27:243N-27:244, 27:247-27:250, 27:252-27:259, 27:261N-27:267, 35:329, 37:01:01:01-37:01:01:19, 37:01:03-37:04:02, 37:06:01-37:09, 37:12-37:13, 37:15-37:33N, 37:35-37:36, 37:38-37:66, 37:68-37:99, 37:101-37:108, 38:17, 40:188, 44:257, 47:01:01:02-47:01:05, 47:05-47:10, 47:12-47:13, 53:03, 53:55, 55:90, 55:121, 56:46
7	350 bp	1070 bp	HLA-B ^{Bw6+}	B*07:02:01:01-07:02:05, 07:02:07-07:02:77, 07:02:79-07:26, 07:28-07:35, 07:37:01-07:37:02, 07:39-07:80, 07:82-07:148, 07:150-07:179, 07:181N-07:191, 07:193-07:218, 07:220-07:235, 07:237-07:272N, 07:274-07:452, 07:454-07:483, 08:01:01:01-08:01:71, 08:04:01-08:05, 08:07-08:51, 08:53:01-08:77, 08:79:01-08:116, 08:118-08:125, 08:127-08:130, 08:132-08:135, 08:137-08:138,



104.201-12 – including Taq polymerase
104.201-12u – without Taq polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: 5S6

Lot-specific information

	<p>08:140-08:152, 08:154-08:156, 08:158-08:254, 08:256-08:270Q, 08:272-08:311, 13:09, 13:39, 13:67, 14:01:01:01-14:92, 14:94-14:117, 14:119-14:120, 15:01:01:01-15:01:04, 15:01:06-15:01:70, 15:01:72-15:12:03, 15:14-15:15:01:02, 15:18:01:01-15:21:01:02, 15:25:01:01-15:35:02, 15:37-15:40:02, 15:42, 15:44-15:58, 15:60-15:66, 15:68-15:86, 15:88, 15:90-15:94N, 15:96-15:99, 15:101-15:114, 15:116-15:129, 15:131-15:156, 15:158-15:161, 15:163-15:167, 15:169-15:176, 15:178-15:195, 15:197:01-15:207, 15:209N-15:215, 15:217-15:221, 15:223-15:229, 15:231-15:253, 15:255, 15:257-15:267, 15:269-15:272N, 15:274-15:276, 15:278-15:338, 15:340-15:355, 15:357-15:360, 15:363:01-15:376, 15:378-15:395, 15:397-15:402, 15:404-15:407, 15:409-15:410, 15:412-15:417, 15:419-15:422, 15:425-15:429, 15:431-15:441, 15:443-15:445, 15:447-15:461, 15:463N-15:499, 15:501-15:504:03, 15:506-15:515, 15:517-15:522, 15:524-15:531, 15:533:01-15:545, 15:547-15:549N, 15:551-15:554, 15:556-15:574, 15:576-15:585, 15:587-15:593, 15:595-15:601, 15:604N-15:612, 15:614:01:01-15:618, 15:620-15:641, 15:643, 15:645-15:654, 15:656-15:668, 15:670-15:672, 18:01:01:01-18:08, 18:10-18:15, 18:17N-18:53, 18:55-18:66, 18:68-18:135:01:02, 18:137-18:178, 18:180-18:193, 18:196-18:232, 27:08, 27:12:01:01-27:12:01:03, 27:18, 27:26, 27:33, 27:40, 27:42, 27:44, 27:89, 27:153, 27:165^w, 27:204:01:01-27:204:01:02, 27:242, 35:01:01:01-35:01:38, 35:01:40-35:02:08, 35:02:10-35:43:01, 35:43:03-35:72, 35:74-35:221, 35:223-35:247:02, 35:249-35:292, 35:294-35:328, 35:330-35:423, 35:425-35:470, 35:472-35:521, 35:523-35:524, 35:526-35:569, 35:571-35:586, 37:05, 37:11, 37:14^w, 37:37, 37:67, 39:01:01:01-39:01:01:29, 39:01:03:01-39:01:14, 39:01:16-39:20, 39:22-39:103, 39:105-39:200, 40:01:01-40:12:02, 40:14:01-40:16:01:02, 40:18, 40:20:01:01-40:40, 40:42-40:46, 40:48-40:75, 40:77-40:95, 40:97-40:108, 40:111-40:116, 40:118N-40:156, 40:158-40:187, 40:189-40:200, 40:202-40:291N, 40:293-40:339, 40:341-40:393, 40:395-40:399N, 40:401-40:547, 41:01:01:01-41:25, 41:27-41:45N, 41:47-41:59, 41:61-41:82, 42:01:01:01-42:02:02, 42:04-42:21, 42:23-42:34, 44:09, 44:46:01-44:46:02, 44:75, 44:90, 44:129, 44:131, 44:254, 44:277, 44:356, 44:438N,</p>
--	--



104.201-12 – including Taq polymerase

104.201-12u – without Taq polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: 5S6

Lot-specific information

			45:01:01:01-45:01:08, 45:01:10-45:15, 45:17-45:25, 45:27-45:32, 46:01:01:01- 46:99, 47:02, 47:03 ^w , 48:01:01:01-48:17, 48:19-48:55, 48:57-48:58, 50:01:01:01- 50:02:01:02, 50:04:01-50:22, 50:31-50:79, 54:01:01:01-54:11, 54:13-54:46, 55:01:01:01-55:05, 55:07-55:89N, 55:91- 55:102, 55:104-55:120, 55:122-55:133, 56:01:01:01-56:06, 56:08-56:20:02, 56:22- 56:45, 56:47-56:64, 56:66-56:95, 57:12, 58:64, 67:01:01-67:07, 73:01:01:01-73:03, 78:01:01:02-78:10, 81:01:01:01-81:10, 82:01:01:01-82:04, 83:01
8⁶	-	-	Negative Control

¹Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of KIR HLA Ligand SSP typings.

When the primers in a primer mix can give rise to HLA-specific PCR products of more than one length this is indicated if the size difference is more than 20 base pairs. Size differences of 20 base pairs or less are not given. For high resolution SSP kits, the alleles listed are specified according to amplicon length.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings. Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

²The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

³For several HLA Class I alleles 1st and/or 4th exon(s) and beyond, as well as intron nucleotide sequences, are not available. In these instances it is not known whether some of the primers of the SSP sets are completely matched with the target sequences or not. Assumption is made that unknown sequences in these regions are conserved within allelic groups.

⁴A minor subset of rare B and C alleles with the listed target motifs will not be amplified by the kit due to downstream sequence variations.

⁵Primer mixes 3 and 4 may have tendencies of unspecific amplifications.

⁶Primer mix 8 contains a negative control, which will amplify the majority of HLA amplicons as well as the amplicons generated by the control primer pairs matching the human growth hormone gene. HLA-specific PCR product sizes range from 75 to 200 base pairs and the PCR product generated by the HGH positive control primer pair is 200 base pairs.

⁷This lot will not amplify the C*01:46 allele in primer mix 1.

⁸The alleles C*05:32 (80^{Arg}), C*15:60 (80^{Gln}) and C*15:71(80^{Ile}) will be amplified in primer mix 2.

Abbreviations

w: might be weakly amplified.

Asn: asparagine

Asp: aspartic acid

Ile: isoleucine

Lys: lysine

Thr: threonine



104.201-12 – including *Taq* polymerase

104.201-12u – without *Taq* polymerase

Lot No.: **5S6**

Visit www.caredx.com for

“Instructions for Use” (IFU)

Lot-specific information

PRIMER SPECIFICATION

Well No.	1	2	3	4	5	6	7
Length of spec. PCR product	345	350	350	350	370	350	350
Length of int. pos. control ¹	800	800	800	1070	1070	1070	1070
5'-primer(s) ²	1 st I 5' -CgA 3'	1 st I 5' -CgA 3'	1 st I 5' -CAg 3'	1 st I 5' -CAg 3'	1 st I 5' -gCA 3'	1 st I 5' -CAg 3'	1 st I 5' -CAg 3'
3'-primer(s) ³	310 5' -gTT 3'	312 5' -AgT 3'	309 5' -gTg 3'	309 5' -ATC 3'	317 5' -ggA 3'	310 5' -ggT 3'	311 5' -ggT 3'
	311 5' -gAT 3'	312 5' -AgT 3'	312 5' -gCC 3'	312 5' -gCA 3'			
	311 5' -ggT 3'	312 5' -AgT 3'	313 5' -Cgg 3'				
	316 5' -gCT 3'		315 5' -AgT 3'				
Well No.	1	2	3	4	5	6	7

¹The internal positive control primer pairs amplify segments of the human growth hormone gene. The internal positive control bands are 1070 or 800 base pairs respectively, well distribution as outlined in the table. Well number 1 contains the shorter, 800 bp, internal positive control band. The well distribution of the internal controls can help in orientation of the kit on gel photo, as well as allow for kit identification. In the presence of a specific amplification the intensity of the control band often decreases.

²The nucleotide position matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.

³The nucleotide position matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the www.ebi.ac.uk/imgt/hla web site. The sequence of the 3 terminal nucleotides of the primer is given.



104.201-12 – including *Taq* polymerase

104.201-12u – without *Taq* polymerase

Lot No.: **5S6**

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot-specific information

CELL LINE VALIDATION SHEET		KIR HLA Ligand primer set²							
		Well							
		1	2	3	4	5	6	7	
		Prod. No.:	202358101	202358102	202358103	202358104	202358105	202358106	202358107
IHWC cell line¹									
1	9001 SA	+	-	-	-	+	-	+	
2	9280 LK707	+	+	-	+	-	-	+	
3	9011 E4181324	+	-	-	+	-	-	-	
4	9275 GU373	+	+	-	+	-	-	+	
5	9009 KAS011	-	+	-	-	-	+	-	
6	9353 SM	+	-	-	+	-	-	+	
7	9020 QBL	-	+	-	-	-	-	+	
8	9025 DEU	-	+	-	-	-	-	+	
9	9026 YAR	+	-	-	+	-	-	-	
10	9107 LKT3	+	-	-	-	+	-	+	
11	9051 PITOUT	+	-	+	-	-	-	-	
12	9052 DBB	-	+	-	+	-	-	-	
13	9004 JESTHOM	+	-	-	-	-	+	-	
14	9071 OLG A	+	-	-	-	-	-	+	
15	9075 DKB	+	-	-	-	+	-	+	
16	9037 SWEIG007	-	+	-	-	-	-	+	
17	9282 CTM3953540	+	-	-	-	-	-	+	
18	9257 32367	+	-	-	-	-	-	+	
19	9038 BM16	+	-	-	-	-	-	+	
20	9059 SLE005	+	-	-	-	-	-	+	
21	9064 AMALA	+	-	-	-	-	-	+	
22	9056 KOSE	+	-	-	-	-	-	+	
23	9124 IHL	+	+	-	-	-	-	+	
24	9035 JBUSH	+	-	-	+	+	-	-	
25	9049 IBW9	+	-	-	-	-	-	+	
26	9285 WT49	+	-	-	+	-	-	-	
27	9191 CH1007	+	+	-	+	+	-	+	
28	9320 BEL5GB	+	+	+	-	-	-	-	
29	9050 MOU	+	-	+	-	-	-	-	
30	9021 RSH	-	+	-	-	-	-	+	
31	9019 DUCAF	-	+	-	-	-	-	+	
32	9297 HAG	-	+	-	-	-	-	+	
33	9098 MT14B	+	-	-	-	-	-	+	
34	9104 DHIF	+	-	-	+	-	-	-	
35	9302 SSTO	-	+	+	-	+	-	-	
36	9024 KT17	+	+	-	-	-	-	+	
37	9065 HHKB	+	-	-	-	-	-	+	
38	9099 LZL	+	-	-	-	-	-	+	
39	9315 CML	+	+	-	-	-	+	+	
40	9134 WHONP199	+	+	+	-	-	-	+	
41	9055 H0301	+	-	-	-	-	-	+	
42	9066 TAB089	+	-	-	-	-	-	+	
43	9076 T7526	+	-	-	-	-	-	+	
44	9057 TEM	+	-	-	+	-	-	-	
45	9239 SHJO	-	+	-	-	+	-	+	
46	9013 SCHU	+	-	-	-	-	-	+	
47	9045 TUBO	+	+	-	+	-	-	-	
48	9303 TER-ND	+	+	+	-	-	-	+	

¹The provided cell line HLA specificities are retrieved from the <http://www.ihwg.org/hla> web site. The specificity of an individual cell line may thus be subject to change.

²The specificity of each primer solution in the kit has been tested against 48 well characterized cell line DNAs and where applicable, additional cell line DNAs.

In primer solutions 1 to 4 one, two or three of the 3'-primers were not possible to be tested.



104.201-12 – including *Taq* polymerase

104.201-12u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **5S6**

Lot-specific information

TRADEMARKS USED IN THIS DOCUMENT/PRODUCT

Olerup SSP[®] is a registered trademark of *CareDx* AB.

Qiagen[™] is a trademark of QIAGEN.

WARRANTY

CareDx AB warrants its products to the original purchaser against defects in materials and workmanship under normal use and application. *CareDx* AB's sole obligation under this warranty shall be to replace, at no charge, any product that does not meet the performance standards stated on the product specification sheet.

This warranty applies only to products that have been handled and stored in accordance with *CareDx* AB's recommendations, and does not apply to products that have been the subject of alternation, misuse, or abuse.

All claims under this warranty must be directed to *CareDx* AB in writing and must be accompanied by a copy of the purchaser's invoice. This warranty is in lieu of all other warranties, expressed or implied, including the warranties of merchantability and fitness for a particular purpose. In no case shall *CareDx* AB be liable for incidental or consequential damages.

This product may not be reformulated, repacked or resold in any form without the written consent of *CareDx* AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Handle all samples as if capable of transmitting disease. All work should be performed wearing gloves and appropriate protection.

GUARANTEE

CareDx AB guarantees that the primers in the *Olerup* SSP[®] typing trays have the specificities given in the lot-specific Specificity and Interpretation Tables of the product insert.

When stored at –20°C, the dried primers are stable for 48 months from the date of manufacture.

When stored at –20°C, the PCR Master Mix including *Taq* polymerase and the PCR Master Mix without *Taq* polymerase are stable for 51 months from the date of manufacture.



104.201-12 – including *Taq* polymerase

104.201-12u – without *Taq* polymerase

Lot No.: **5S6**

Lot-specific information

Visit www.caredx.com for
“Instructions for Use” (IFU)

ADDRESSES:

Manufacturer:

Caredx AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Tel: +46-8-508 939 00

Fax: +46-8-717 88 18

E-mail: orders-se@caredx.com

Web page: www.caredx.com

CareDx Lab Solutions Inc., 901 S. Bolmar St., Suite R, West Chester, PA 19382

Tel: 1-877-653-78171

Fax: 610-344-7989

E-mail: orders-us@caredx.com

Web page: www.caredx.com

For information on CareDx distributors worldwide, contact **CareDx AB**.

